Management of Prednisone‑Induced Insomnia

Non‑Pharmacologic First‑Line Therapy

Cognitive‑behavioral therapy for insomnia (CBT‑I) is mandated as the first‑line treatment for all adults with chronic, medication‑induced insomnia by the American College of Physicians and the American Academy of Sleep Medicine, because it provides superior long‑term efficacy compared with pharmacotherapy alone. [1][2]3
Core CBT‑I components – stimulus‑control (use the bed only for sleep; leave the bedroom if unable to fall asleep within ~20 min), sleep‑restriction (limit time in bed to actual sleep time + 30 min and expand gradually as efficiency improves), relaxation techniques (progressive muscle relaxation, guided imagery, breathing exercises), and cognitive restructuring (address anxiety and maladaptive beliefs about sleep). These elements are supported by high‑quality evidence from the American Academy of Sleep Medicine. [2][3]
CBT‑I can be delivered effectively via individual therapy, group sessions, telephone‑based programs, web‑based modules, or self‑help books; all formats demonstrate comparable outcomes. [2][3]

Low‑dose doxepin (3 – 6 mg at bedtime) is the preferred first‑line hypnotic for prednisone‑induced insomnia, especially when nocturnal awakenings or early‑morning awakenings predominate. 4
At these hypnotic doses, doxepin reduces wake after sleep onset by ~22–23 min and increases total sleep time by ~26–32 min, with minimal side‑effects and no abuse potential. 4
Doxepin at 3–6 mg exhibits minimal anticholinergic activity, making it safer than higher antidepressant doses or over‑the‑counter antihistamines. 4
Initiate doxepin at 3 mg; if sleep improvement is insufficient after 1–2 weeks, titrate to 6 mg. 4

Sleep‑onset difficulty:
- Ramelteon 8 mg at bedtime (melatonin‑receptor agonist) – no abuse potential, no DEA scheduling, no withdrawal symptoms. 4
- Zaleplon 10 mg (5 mg if age ≥ 65 y) – very short half‑life (~1 h) provides rapid sleep initiation with minimal next‑day sedation. 4
- Zolpidem 10 mg (5 mg if age ≥ 65 y) – shortens sleep‑onset latency by ~25 min and adds ~29 min to total sleep time. 4
Combined sleep‑onset and maintenance problems:
- Eszopiclone 2–3 mg (1 mg if age ≥ 65 y or hepatic impairment) – improves both onset and maintenance, increasing total sleep time by 28–57 min; take within 30 min of bedtime with ≥7 h remaining before planned awakening. 4
When hyperarousal is prominent and other agents are unsuitable:
- Suvorexant 10 mg (orexin‑receptor antagonist) – reduces wake after sleep onset by 16–28 min via a mechanism distinct from benzodiazepine‑type agents. 4

Trazodone – yields only ~10 min reduction in sleep latency, provides no subjective quality improvement, and causes adverse events in ~75 % of older adults; the American Academy of Sleep Medicine advises against its use. 4
Over‑the‑counter antihistamines (diphenhydramine, doxylamine) – lack efficacy data, produce strong anticholinergic effects (confusion, urinary retention, falls), and develop tolerance after 3–4 days. 4
Traditional benzodiazepines (lorazepam, clonazepam, diazepam) – long half‑lives lead to drug accumulation, daytime sedation, higher fall and cognitive‑impairment risk, and are linked to dementia and fractures; therefore they should be avoided. 4
Antipsychotics (quetiapine, olanzapine) – weak evidence for insomnia benefit and significant metabolic, weight‑gain, and mortality risks, especially in the elderly; not recommended for primary insomnia. 4
Melatonin supplements – produce only ~9 min reduction in sleep latency with insufficient supporting evidence; guidelines advise against routine use. 4

Reassess sleep parameters (sleep‑onset latency, total sleep time, nocturnal awakenings) and daytime functioning after 1–2 weeks of any hypnotic, and monitor for adverse effects such as morning sedation or cognitive impairment. 4
Prescribe the lowest effective dose for the shortest necessary period (generally ≤ 4 weeks initially), in line with FDA labeling for hypnotics. 4
Screen for complex sleep behaviors (e.g., sleep‑driving, sleep‑walking, sleep‑eating) at every visit; discontinue the medication immediately if such behaviors occur. 4
All hypnotics carry risks of daytime impairment, falls, fractures, and cognitive decline, which are amplified in patients receiving corticosteroids; clinicians must weigh these risks carefully. 4
When discontinuing a hypnotic, taper gradually and employ CBT‑I techniques to prevent rebound insomnia. 4

Adding a hypnotic before optimizing prednisone timing (morning‑only dosing) perpetuates the primary cause of insomnia.
Initiating pharmacologic therapy without first implementing CBT‑I leads to less durable benefit and missed opportunity for non‑pharmacologic resolution. [1][2]3
Using adult dosing in older adults; age‑adjusted dosing (e.g., doxepin ≤ 6 mg, zolpidem ≤ 5 mg, eszopiclone ≤ 2 mg for age ≥ 65 y) is essential to reduce fall risk. 4
Prescribing agents that guidelines explicitly advise against (trazodone, OTC antihistamines, benzodiazepines, antipsychotics) exposes patients to unnecessary harm without proven benefit. 4
Continuing hypnotic therapy long‑term without periodic reassessment; efficacy, side‑effects, and ongoing need should be evaluated every 2–4 weeks. 4